Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non-Hodgkin lymphomas: A phase IB/II study

TY - JOUR

T1 - Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non-Hodgkin lymphomas

T2 - A phase IB/II study

AU - Phillips, Tycel

AU - Brunvand, Mark

AU - Chen, Andy I.

AU - Essell, James

AU - Chiappella, Annalisa

AU - Diefenbach, Catherine

AU - Cheng, Ji

AU - Ramies, David

AU - Hirata, Jamie

AU - Morschhauser, Franck

AU - Flinn, Ian W.

N1 - Funding Information: The authors would like to thank the participating patients and their families, study investigators, and research nurses. The study was designed by the funder (F. Hoffmann‐La Roche Ltd) and academic authors. Data were collected by the academic authors and their research teams and were interpreted by the authors and the funder. The corresponding author had full access to the data in the study and had final responsibility for the decision to submit for publication. Third‐party medical writing assistance, under the direction of the authors, was provided by Angela Rogers, PhD, and Claire Lavin, PhD, on behalf of Ashfield MedComms, an Ashfield Health company, and was funded by F. Hoffmann‐La Roche Ltd. Funding Information: Tycel Phillips has received research support from AbbVie and Pharmacyclics, and reports advisory board participation for Genentech, Inc., Bayer, Gilead, Pharmacyclics, Incyte, and Seattle Genetics. Mark Brunvand has no disclosures; the clinical and intellectual work on this paper was performed prior to employment with the Cigna Corporation and does not reflect the opinions or support of the Cigna Corporation. Andy I. Chen has acted as a consultant and has received research funding from Genentech, Inc. James Essell has nothing to disclose. Annalisa Chiappella reports advisory board participation for Celgene, Janssen, and iQone, and has received lecture fees from Celgene, Janssen, F. Hoffmann‐La Roche Ltd, and Servier. Catherine Diefenbach has served as a consultant/advisory board participant for Bristol‐Myers Squibb, Celgene, Merck, Genentech, Inc./F. Hoffmann‐La Roche Ltd, and Seattle Genetics, and has received research support from Seattle Genetics, Bristol‐Myers Squibb, Merck, Genentech, Inc., Incyte, LAM Therapeutics, Millennium/Takeda, MEI Pharma, and Trillium. Ji Cheng is an employee of F. Hoffmann‐La Roche Ltd. David Ramies was a consultant to Genentech, Inc. at the time the study was carried out. Jamie Hirata is an employee of Genentech, Inc. Franck Morschhauser has participated in advisory boards for Celgene, F. Hoffmann‐La Roche Ltd, Gilead, Bristol‐Myers Squibb, Epizyme, and Bayer, and reports receiving lecture fees from Celgene, Janssen, F. Hoffmann‐La Roche Ltd, and Novartis, and research support from AbbVie, Pharmacyclics, and advisory board fees from Genentech, Inc., Bayer, Gilead, Pharmacyclics, Incyte, and Seattle Genetics. Ian W. Flinn has acted as a consultant for AbbVie, Seattle Genetics, TG Therapeutics, and Verastem Oncology, and has received research funding from Acerta Pharma, Agios, Calithera Biosciences, Celgene, Constellation Pharmaceuticals, Genentech, Inc., Gilead Sciences, Incyte, Infinity Pharmaceuticals, Janssen, Karo Pharma, Kite Pharma, Novartis, Pharmacyclics, Portola Pharmaceuticals, F. Hoffmann‐La Roche Ltd, TG Therapeutics, Trillium Therapeutics, AbbVie, ArQule, BeiGene, Curis Inc., FORMA Therapeutics, Forty Seven, Merck, Pfizer, Takeda, Teva, Verastem Oncology, Gilead Sciences, AstraZeneca, Juno Therapeutics, Unum Therapeutics, and MorphoSys AG.

PY - 2022/1/1

Y1 - 2022/1/1

UR - http://www.scopus.com/inward/record.url?scp=85120166195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85120166195&partnerID=8YFLogxK

U2 - 10.1002/ajh.26400

DO - 10.1002/ajh.26400

M3 - Letter

C2 - 34731510

AN - SCOPUS:85120166195

SN - 0361-8609

VL - 97

SP - E24-E27

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 1

ER -